Efficacy and Safety of Adding Clopidogrel to Aspirin on Stroke Prevention among High Vascular Risk Patients: A Meta-Analysis of Randomized Controlled Trials

被引:3
作者
Chen, Shuying [1 ]
Shen, Qingyu [2 ]
Tang, Yamei [1 ]
He, Lei [1 ]
Li, Yi [1 ]
Li, Hui [3 ]
Li, Mei [1 ]
Peng, Ying [1 ]
机构
[1] Sun Yat Sen Univ, Dept Neurol, Sun Yat Sen Mem Hosp, Guangzhou 510275, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Dept Neurol, Affiliated Boji Hosp, Guangzhou 510275, Guangdong, Peoples R China
[3] Guangdong Gen Hosp, Dept Neurol, Guangzhou, Guangdong, Peoples R China
关键词
DUAL ANTIPLATELET THERAPY; TRANSIENT ISCHEMIC ATTACK; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; RATIONALE; DESIGN; SURGERY;
D O I
10.1371/journal.pone.0104402
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives: Whether clopidogrel should be added to aspirin for stroke prevention remained controversial for the risk of hemorrhagic complications. This meta-analysis was aimed to assess the efficacy and safety of adding clopidogrel to aspirin on stroke prevention in high vascular risk patients, and to provide evidence for a suitable duration of dual antiplatelet therapy. Methods: We searched PubMed, EMBase, OVID and Cochrane Central Register of Controlled Trials (up to June, 2013) for randomized controlled trials evaluating the efficacy and safety of clopidogrel plus aspirin versus aspirin alone in high vascular risk patients. Comparisons of stroke and hemorrhagic complications between treatment groups were expressed by the pooled Relative Risks (RRs) with 95% Confidence Intervals (CIs). Results: Fifteen trials with a total of 97692 intention-to-treat participants were included with duration of follow-up ranging from 7 days to 3.6 years. Dual antiplatelet therapy reduced all stroke by 21% (RR: 0.79, 95% CI: 0.73-0.85) with no evidence of heterogeneity across the trials (P = 0.27, I-2 = 17%). The effects were consistent between short-term subgroup (<= 1 month, RR: 0.76, 95% CI: 0.67-0.85) and long-term subgroup (>= 3 months, RR: 0.81, 95% CI: 0.73-0.89). The risk of major bleeding was not significantly increased by dual antiplatelet therapy in short-term subgroup (RR: 1.11, 95% CI: 0.91-1.36), while significantly increased in long-term subgroup (RR: 1.52, 95% CI: 1.36-1.69). Long-term dual antiplatelet therapy substantially increased the risk of intracranial bleeding (RR: 1.76, 95% CI: 1.22-2.54). Conclusions: This meta-analysis demonstrates that short-term combination of clopidogrel and aspirin is effective and safe for stroke prevention in high vascular risk patients. Long-term combination therapy substantially increases the risk of major bleeding and intracranial bleeding.
引用
收藏
页数:10
相关论文
共 33 条
[1]   Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial [J].
Belch, Jill J. F. ;
Dormandy, John .
JOURNAL OF VASCULAR SURGERY, 2010, 52 (04) :825-833
[2]   Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke [J].
Benavente, Oscar R. ;
Hart, Robert G. ;
McClure, Leslie A. ;
Szychowski, Jeffrey M. ;
Coffey, Christopher S. ;
Pearce, Lesly A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (09) :817-825
[3]   The Secondary Prevention of Small Subcortical Strokes (SPS3) study [J].
Benavente, Oscar R. ;
White, Carole L. ;
Pearce, Lesly ;
Pergola, Pablo ;
Roldan, Ana ;
Benavente, Marie-France ;
Coffey, Christopher ;
McClure, Leslie A. ;
Szychowski, Jeff M. ;
Conwit, Robin ;
Heberling, Patricia A. ;
Howard, George ;
Bazan, Carlos ;
Vidal-Pergola, Gabriela ;
Talbert, Robert ;
Hart, Robert G. .
INTERNATIONAL JOURNAL OF STROKE, 2011, 6 (02) :164-175
[4]   Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events [J].
Bhatt, DL ;
Fox, KAA ;
Hacke, W ;
Berger, PB ;
Black, HR ;
Boden, WE ;
Cacoub, P ;
Cohen, EA ;
Creager, MA ;
Easton, JD ;
Flather, MD ;
Haffner, SM ;
Hamm, CW ;
Hankey, GJ ;
Johnston, SC ;
Mak, KH ;
Mas, JL ;
Montalescot, G ;
Pearson, TA ;
Steg, PG ;
Steinhubl, SR ;
Weber, MA ;
Brennan, DM ;
Fabry-Ribaudo, L ;
Booth, J ;
Topol, EJ ;
Frye, RL ;
Amarenco, P ;
Brass, LM ;
Buyse, M ;
Cohen, LS ;
DeMets, DL ;
Fuster, V ;
Hart, RG ;
Marler, JR ;
McCarthy, C ;
Schoemig, A ;
Lincoff, AM ;
Brener, SJ ;
Sila, CA ;
Albuquerque, A ;
Aroutiounov, G ;
Artemiev, D ;
Atkeson, BG ;
Bartel, T ;
Basart, DCG ;
Lima, AB ;
Belli, G ;
Bordalo e Sa, AL ;
Bosch, X .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (16) :1706-1717
[5]   Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial [J].
Bhatt, DL ;
Topol, EJ .
AMERICAN HEART JOURNAL, 2004, 148 (02) :263-268
[6]   Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial [J].
Chen, ZM ;
Jiang, LX ;
Chen, YP ;
Xie, JX ;
Pan, HC ;
Peto, R ;
Collins, R ;
Liu, LS ;
Chen, ZM ;
Liu, LS ;
Collins, R ;
Jiang, LX ;
Chen, YP ;
Xie, JX ;
Pan, HC ;
Peto, R ;
Cai, NS ;
Chen, YZ ;
Cui, JJ ;
Dai, GZ ;
Feng, JZ ;
Fu, SY ;
Gent, M ;
Gong, LS ;
Hu, DY ;
Huang, DJ ;
Huang, J ;
Huang, TG ;
Huang, ZW ;
Hui, RT ;
Jiang, BQ ;
Li, DY ;
Li, SM ;
Li, TD ;
Li, YQ ;
Li, ZQ ;
Liu, YH ;
Meng, QY ;
Qian, TJ ;
San, J ;
Tao, SQ ;
Wang, DW ;
Wang, LH ;
Wang, W ;
Wu, HA ;
Xi, WH ;
Xu, CB ;
Yang, DC ;
Yang, XF ;
Yin, JQ .
LANCET, 2005, 366 (9497) :1607-1621
[7]   Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events [J].
Connolly, S. ;
Yusuf, S. ;
Budaj, A. ;
Camm, J. ;
Chrolavicius, S. ;
Commerford, P. J. ;
Flather, M. ;
Fox, K. A. A. ;
Hart, R. ;
Hohnloser, S. ;
Joyner, C. ;
Pfeffer, M. ;
Anand, I. ;
Arthur, H. ;
Avezum, A. ;
Bethala-Sithya, M. ;
Blumenthal, M. ;
Ceremuzynski, L. ;
De Caterina, R. ;
Diaz, R. ;
Flaker, G. ;
Frangin, G. ;
Franzosi, M. -G. ;
Gaudin, C. ;
Golitsyn, S. ;
Goldhaber, S. ;
Granger, C. ;
Halon, D. ;
Hermosillo, A. ;
Hunt, D. ;
Jansky, P. ;
Karatzas, N. ;
Keltai, M. ;
Lanas, F. ;
Lau, C. P. ;
Le Heuzey, J. -Y. ;
Lewis, B. S. ;
Morais, J. ;
Morillo, C. ;
Oto, A. ;
Paolasso, E. ;
Peters, R. J. ;
Pfisterer, M. ;
Piegas, L. ;
Pipillis, T. ;
Proste, C. ;
Sitkei, E. ;
Swedberg, K. ;
Synhorst, D. ;
Talajic, M. .
AMERICAN HEART JOURNAL, 2006, 151 (06) :1187-1193
[8]   Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation [J].
Connolly, S. J. ;
Yusuf, S. ;
Camm, J. ;
Chrolavicius, S. ;
Commerford, P. ;
Flather, M. ;
Hart, R. G. ;
Hohnloser, S. H. ;
Joyner, C. ;
Pfeffer, M. ;
Gaudin, C. ;
Blumenthal, M. ;
Marchese, C. ;
Pogue, J. ;
Hart, R. ;
Hohnloser, S. ;
Anand, I. ;
Arthur, H. ;
Avezum, A. ;
Budaj, A. ;
Ceremuzynski, L. ;
De Caterina, R. ;
Diaz, R. ;
Dorian, P. ;
Flaker, G. ;
Fox, K. A. A. ;
Franzosi, M. G. ;
Goldhaber, S. ;
Golitsyn, S. ;
Granger, C. ;
Halon, D. ;
Hermosillo, A. ;
Hunt, D. ;
Jansky, P. ;
Karatzas, N. ;
Keltai, M. ;
Kozan, O. ;
Lanas, F. ;
Lau, P. ;
Le Heuzey, J. Y. ;
Lewis, B. S. ;
Morais, J. ;
Morillo, C. ;
Paolasso, E. ;
Peters, R. J. ;
Pfisterer, M. ;
Piegas, L. ;
Pipilis, A. ;
Sitkei, E. ;
Swedberg, K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (20) :2066-2078
[9]   Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis [J].
Duval, S ;
Tweedie, R .
BIOMETRICS, 2000, 56 (02) :455-463
[10]   A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) [J].
Gent, M ;
Beaumont, D ;
Blanchard, J ;
Bousser, MG ;
Coffman, J ;
Easton, JD ;
Hampton, JR ;
Harker, LA ;
Janzon, L ;
Kusmierek, JJE ;
Panak, E ;
Roberts, RS ;
Shannon, JS ;
Sicurella, J ;
Tognoni, G ;
Topol, EJ ;
Verstraete, M ;
Warlow, C .
LANCET, 1996, 348 (9038) :1329-1339